T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.4% |
| 2 | Healthcare | 16.1% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CDK
1576
DELISTED
CDK Global, Inc.
CDK
| $3.02M | ﹤0.01% |
72,453
+3,457
| +5% | +$145K |
|
1577
Chemours
CC
$2.38B
| $3.01M | ﹤0.01% |
89,705
+874
| +1% | +$27.2K |
|
1578
Jabil
JBL
$38.6B
| $3.01M | ﹤0.01% |
42,742
-2,148
| -5% | -$136K |
|
1579
Autoliv
ALV
$8.95B
| $2.99M | ﹤0.01% |
28,952
-362
| -1% | -$35.5K |
|
1580
Novartis
NVS
$284B
| $2.99M | ﹤0.01% |
34,209
+890
| +3% | +$73.9K |
|
|
SFIX
1581
Stitch Fix
SFIX
$484M
| $2.97M | ﹤0.01% |
157,121
-95,143
| -38% | -$2.73M |
|
1582
Polaris
PII
$3.92B
| $2.97M | ﹤0.01% |
27,024
-1,484
| -5% | -$175K |
|
1583
Arrowhead Research
ARWR
$11.9B
| $2.96M | ﹤0.01% |
44,657
-3,010
| -6% | -$207K |
|
|
SRC
1584
DELISTED
SPIRIT REALTY CAPITAL, INC.
SRC
| $2.94M | ﹤0.01% |
60,934
-2,888
| -5% | -$137K |
|
1585
First Citizens BancShares
FCNCA
$25.8B
| $2.92M | ﹤0.01% |
3,525
-389
| -10% | -$324K |
|
1586
Yeti Holdings
YETI
$3.43B
| $2.92M | ﹤0.01% |
35,288
-2,662
| -7% | -$244K |
|
1587
American States Water
AWR
$3.52B
| $2.92M | ﹤0.01% |
28,179
+2,655
| +10% | +$250K |
|
1588
Toyota
TM
$226B
| $2.91M | ﹤0.01% |
15,687
+1,509
| +11% | +$271K |
|
1589
Cullen/Frost Bankers
CFR
$10.6B
| $2.9M | ﹤0.01% |
23,011
-836
| -4% | -$108K |
|
1590
Ambarella
AMBA
$3.61B
| $2.9M | ﹤0.01% |
14,294
-1,067
| -7% | -$198K |
|
|
WBT
1591
DELISTED
Welbilt, Inc.
WBT
| $2.88M | ﹤0.01% |
121,007
-2,324
| -2% | -$55K |
|
1592
PagerDuty
PD
$917M
| $2.87M | ﹤0.01% |
82,520
+2,659
| +3% | +$103K |
|
1593
Hancock Whitney
HWC
$6.41B
| $2.87M | ﹤0.01% |
57,270
+15,790
| +38% | +$788K |
|
1594
SEI Investments
SEIC
$12.7B
| $2.86M | ﹤0.01% |
46,938
-5,969
| -11% | -$370K |
|
1595
CytomX Therapeutics
CTMX
$719M
| $2.86M | ﹤0.01% |
659,863
-2,802
| -0.4% | -$16.4K |
|
1596
Fox Factory Holding Corp
FOXF
$888M
| $2.85M | ﹤0.01% |
16,764
-1,105
| -6% | -$185K |
|
|
SPR
1597
DELISTED
Spirit AeroSystems
SPR
| $2.85M | ﹤0.01% |
66,097
-5,955
| -8% | -$255K |
|
1598
Americold
COLD
$4.32B
| $2.84M | ﹤0.01% |
86,731
-22,183
| -20% | -$686K |
|
1599
KB Home
KBH
$3.44B
| $2.84M | ﹤0.01% |
63,548
-17,738
| -22% | -$743K |
|
|
ADVWW
1600
DELISTED
Advantage Solutions Warrant
ADVWW
| $2.83M | ﹤0.01% |
1,144,439
-3,472
| -0.3% | -$6.84K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.